113 filings
Page 3 of 6
8-K
85ccxkozjh zdjv
14 Apr 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:10pm
8-K
6e94epasrjrdg
28 Mar 23
Virpax Pharmaceuticals Announces Appointment of
4:05pm
8-K
iyt63i z8wbdc
22 Mar 23
Virpax Pharmaceuticals Reports 2022 Year-End Results
9:00am
8-K
4a2rr 02694a4ad5k
13 Mar 23
Regulation FD Disclosure
9:11am
8-K
xhx0sokq
17 Feb 23
Other Events
9:02am
8-K
z51t8v4qxp
29 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:10pm
S-8
kpg uw815y25d1lmj
22 Nov 22
Registration of securities for employees
4:06pm
8-K
5sowq6p5n07v8uxy
9 Nov 22
Virpax Pharmaceuticals Reports 2022 Third Quarter Results
9:05am
EFFECT
vtr6msou2a
19 Oct 22
Notice of effectiveness
12:15am
CORRESP
q0kz5cl
14 Oct 22
Correspondence with SEC
12:00am
UPLOAD
bh0f 368ri11j1
13 Oct 22
Letter from SEC
12:00am
S-3
r7fyzjk0sbgvh
7 Oct 22
Shelf registration
5:01pm
8-K
mph18z
15 Aug 22
Virpax Pharmaceuticals Reports 2022 Second Quarter Results and Recent Developments
9:10am
8-K
we12l0evvg
25 Jul 22
Departure of Directors or Certain Officers
5:01pm
8-K
kbqgke5hgaps99dk9c
27 Jun 22
Virpax Will Pursue Direct to OTC Pathway for Epoladermâ„¢ for Pain Associated with Osteoarthritis
4:30pm
DEFA14A
0im8sz
21 Jun 22
Additional proxy soliciting materials
4:30pm
DEFA14A
qaie94mv4f 5dr9vd
15 Jun 22
Additional proxy soliciting materials
5:20pm